Compare Stocks

Date Range: 

 CountrywideIntegra ResourcesThe Bank of PrincetonNicoxPoxel
SymbolOTCMKTS:CYWDFOTCMKTS:IRRZFNASDAQ:BPRNOTCMKTS:NICXFOTCMKTS:PXXLF
Price Information
Current Price$5.42$1.50$30.21$5.08$8.00
52 Week RangeN/ABuyBuyN/ABuy
MarketRank™
Overall Score0.41.11.90.50.6
Analysis Score0.03.52.50.00.0
Community Score1.92.02.51.92.3
Dividend Score0.00.02.50.00.0
Ownership Score0.00.00.80.00.0
Earnings & Valuation Score0.00.01.30.60.6
Analyst Ratings
Consensus RecommendationN/ABuyBuyN/ABuy
Consensus Price TargetN/A$3.20$33.33N/AN/A
% Upside from Price TargetN/A113.33% upside10.34% upsideN/AN/A
Trade Information
Market Cap$177.58 million$179.34 million$203.88 million$170.03 million$192.72 million
BetaN/AN/A0.630.880.95
Average VolumeN/A93,09016,553700250
Sales & Book Value
Annual RevenueN/AN/A$63.10 million$9.25 million$88.11 million
Price / SalesN/AN/A3.2418.382.19
CashflowN/AN/AN/AN/A$0.64 per share
Price / CashN/AN/AN/AN/A12.50
Book ValueN/AN/AN/A$4.14 per shareN/A
Price / BookN/AN/A1.23
Profitability
Net IncomeN/A$-16,320,000.00N/A$-21,190,000.00$15.97 million
EPSN/AN/A$1.54($0.69)N/A
Trailing P/E Ratio0.00N/A15.90N/A0.00
Forward P/E Ratio16.16N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/A-93.61%N/AN/AN/A
Return on Assets (ROA)N/A-30.90%N/AN/AN/A
Dividend
Annual PayoutN/AN/A$0.48N/AN/A
Dividend YieldN/AN/A1.59%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A31.17%N/AN/A
Years of Consecutive Dividend GrowthN/AN/A1 YearsN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/A36.48%N/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees7,000201773451
Shares Outstanding32.76 million119.56 million6.76 million33.47 million24.09 million
Next Earnings DateN/AN/A7/22/2021 (Estimated)N/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Poxel (OTCMKTS:PXXLF) Stock Price Down 2%Poxel (OTCMKTS:PXXLF) Stock Price Down 2%
americanbankingnews.com - April 27 at 12:46 AM
Poxel S.A. reports Q1 resultsPoxel S.A. reports Q1 results
seekingalpha.com - April 21 at 12:20 PM
Poxel Reports Financial Results for Full Year 2020 and Provides Corporate UpdatePoxel Reports Financial Results for Full Year 2020 and Provides Corporate Update
finance.yahoo.com - March 24 at 2:57 PM
Poxel Announces Completion of Arbitration with Merck SeronoPoxel Announces Completion of Arbitration with Merck Serono
finance.yahoo.com - February 24 at 7:41 AM
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate UpdatePoxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
finance.yahoo.com - February 12 at 2:25 AM
Poxel Regains Imeglimin Rights From MetavantPoxel Regains Imeglimin Rights From Metavant
finance.yahoo.com - January 14 at 2:35 PM
Poxel Announces Financial Calendar for 2021Poxel Announces Financial Calendar for 2021
finance.yahoo.com - January 5 at 4:45 AM
Poxel SA Stock , PXXLFPoxel SA Stock , PXXLF
markets.businessinsider.com - December 25 at 10:34 PM
Poxel Announces Participation at Upcoming Virtual Investor ConferencesPoxel Announces Participation at Upcoming Virtual Investor Conferences
finance.yahoo.com - December 17 at 8:26 AM
Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASHPoxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH
finance.yahoo.com - December 14 at 3:04 AM
Poxel announces its partner Metavant not to advance Imeglimin into phase 3 programmePoxel announces its partner Metavant not to advance Imeglimin into phase 3 programme
pharmabiz.com - November 23 at 9:07 AM
Ahead of possible Japanese approval, Metavant backs away from Poxel-partnered imegliminAhead of possible Japanese approval, Metavant backs away from Poxel-partnered imeglimin
fiercebiotech.com - November 20 at 9:38 AM
Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020
finance.yahoo.com - November 16 at 1:06 PM
Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020
finance.yahoo.com - November 9 at 2:07 PM
PXXLF After-Hours QuotesPXXLF After-Hours Quotes
nasdaq.com - October 18 at 7:09 PM
Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French GovernmentPoxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government
news.yahoo.com - October 15 at 1:21 PM
Poxel Announces Participation at Upcoming Scientific and Investor ConferencesPoxel Announces Participation at Upcoming Scientific and Investor Conferences
finance.yahoo.com - September 21 at 2:05 PM
Poxel Reports Financial Results for First Half 2020 and Provides a Corporate UpdatePoxel Reports Financial Results for First Half 2020 and Provides a Corporate Update
finance.yahoo.com - September 15 at 2:06 PM
Poxel initiates DESTINY 1 phase 2 trial of pioglitazone to treat NASHPoxel initiates DESTINY 1 phase 2 trial of pioglitazone to treat NASH
pharmabiz.com - September 4 at 10:06 AM
Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020
finance.yahoo.com - September 3 at 1:51 PM
Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven PatientsPoxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients
finance.yahoo.com - September 2 at 7:43 AM
Poxel annonce le dépôt de la demande denregistrement de lImeglimine au JaponPoxel annonce le dépôt de la demande d'enregistrement de l'Imeglimine au Japon
www.msn.com - July 30 at 8:55 AM
Poxel : des fonds gérés par Andera Partners pointent autour de 14% du capitalPoxel : des fonds gérés par Andera Partners pointent autour de 14% du capital
www.boursier.com - July 28 at 6:01 PM
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2020Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2020
finance.yahoo.com - July 21 at 1:40 PM
Poxel Announces Participation in Upcoming Virtual Investor ConferencesPoxel Announces Participation in Upcoming Virtual Investor Conferences
finance.yahoo.com - May 28 at 12:45 PM
DateCompanyBrokerageAction
6/19/2020Integra ResourcesStifel NicolausBoost Price Target
5/3/2021The Bank of PrincetonBoenning ScattergoodUpgrade
4/29/2021The Bank of PrincetonPiper SandlerUpgrade
4/26/2021The Bank of PrincetonB. RileyBoost Price Target
4/23/2019The Bank of PrincetonSandler O'NeillDowngrade
12/16/2019NicoxCantor FitzgeraldInitiated Coverage
1/31/2019NicoxHC WainwrightReiterated Rating
6/23/2020PoxelJMP SecuritiesInitiated Coverage
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.